RNAI TECHNOLOGY MARKET ANALYSIS

Key Developments

• In April 2024, Phio Pharmaceuticals, a clinical-stage biotechnology company, revealed that its INTASYL siRNA gene silencing technology, aimed at enhancing immune cells' ability to combat tumor cells, will be featured in "Viewpoint," a national program hosted by Mr. Dennis Quaid
• In January 2024, Shanghai Argo Biopharmaceutical Co., Ltd. announced two exclusive license and collaboration agreements with Novartis Pharma AG. The first agreement grants Novartis an global exclusive licenses for a Phase 1 program, including a research collaboration.The second agreement provides Novartis with an exclusive ex-Greater China license for a Phase 1/2a clinical-stage program in cardiovascular disease. These assets, developed using Argo's RNAi platform technology, promise leading efficacy and durability in therapies.
• In August 2023, Sirnaomics Ltd., a prominent biopharmaceutical company specializing in RNAi therapeutics, completed all dosing regimens for its Phase I study of STP707. This therapy targets multiple solid tumors in patients with late-stage cancers resistant to previous treatments. Results showed that approximately 74% of evaluable patients achieved stable disease (SD), with some demonstrating reduced tumor burden according to RECIST criteria.